Lymphoma Clinical Trial Results

Browse clinical trials for Lymphoma by phase, sponsor and reported results. Data from ClinicalTrials.gov.

• A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Ri
  Phase 3 · Hoffmann-La Roche · Active, not recruiting · Mar 6, 2026
• Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negati
  Phase 3 · National Cancer Institute (NCI) · Active, not recruiting · Sep 24, 2024
• Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly
  Phase 3 · National Cancer Institute (NCI) · Active, not recruiting · Jun 12, 2025
• Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patient
  Phase 2 · National Cancer Institute (NCI) · Active, not recruiting · Jan 25, 2023
• Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab
  Phase 3 · National Cancer Institute (NCI) · Active, not recruiting · Feb 2, 2026
• An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
  Phase 2 · Acerta Pharma BV · Active, not recruiting · Oct 19, 2018
• Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patie
  Phase 3 · National Cancer Institute (NCI) · Active, not recruiting · Aug 14, 2023
• EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection
  Phase 2 · National Cancer Institute (NCI) · Completed · Jun 28, 2022
• Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating
  Phase 2 · National Cancer Institute (NCI) · Active, not recruiting · Nov 6, 2025
• Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma
  Phase 2 · National Cancer Institute (NCI) · Active, not recruiting · Oct 23, 2023
• Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large
  Phase 3 · National Cancer Institute (NCI) · Active, not recruiting · Sep 30, 2025
• Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
  Phase 1 · UNC Lineberger Comprehensive Cancer Center · Active, not recruiting · Jul 31, 2026
• Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed
  Phase 2 · National Cancer Institute (NCI) · Active, not recruiting · Jun 3, 2021
• Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
  Phase 2 · M.D. Anderson Cancer Center · Terminated · Apr 13, 2021
• 05-001: Treatment of Acute Lymphoblastic Leukemia in Children
  Phase 3 · Dana-Farber Cancer Institute · Completed · Jun 14, 2017

Trials by condition

Lung CancerNon-Small Cell Lung CancerBreast CancerColorectal CancerGastric CancerLiver CancerPancreatic CancerProstate CancerOvarian CancerMelanomaLeukemiaLymphomaMultiple MyelomaGlioblastomaType 2 DiabetesObesityHypertensionHeart FailureAtrial FibrillationStrokeChronic Kidney DiseaseNASH / MASHAlzheimer’s DiseaseParkinson’s DiseaseMultiple SclerosisDepressionEpilepsyALSRheumatoid ArthritisPsoriasisAtopic DermatitisCrohn’s DiseaseUlcerative ColitisLupusAsthmaCOPD

All trials